+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting Granulocyte-Colony Stimulating Factor Market - Global Forecast to 2030- Product Image
Long-acting Granulocyte-Colony Stimulating Factor Market - Global Forecast to 2030- Product Image
Sale

Long-acting Granulocyte-Colony Stimulating Factor Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6136929
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The long-acting granulocyte-colony stimulating factor (G-CSF) market is evolving rapidly, driven by advances in sustained-release therapies and growing demand for efficient, patient-centered supportive oncology solutions. Senior decision-makers need a streamlined overview of critical forces, current segmentation, and actionable insights to inform strategic direction.

Market Snapshot: Long-Acting Granulocyte-Colony Stimulating Factor

Long-acting G-CSF is reshaping neutropenia management by extending dosing intervals and optimizing adherence. Recent years have seen a transition from short-acting to sustained-release formulations, supported by innovation in delivery technologies, biosimilar introduction, and digital health integration. Regulatory shifts worldwide and changing procurement practices are defining updated standards for clinical outcomes and market access. Manufacturers and healthcare providers are navigating increased price competition, complexity in supply chains, and heightened demand for tailored oncology care. The landscape is marked by robust innovation, regional adoption variations, and a strong focus on stakeholder collaboration.

Scope & Segmentation

  • Product Types: Includes originator and biosimilar molecules such as lipegfilgrastim and pegfilgrastim.
  • Applications: Focus on chemotherapy-induced neutropenia—subdivided into hematological malignancies and solid tumors—as well as prophylaxis in surgical patients.
  • End Users: Comprises homecare settings, community and tertiary hospitals, research institutes, day care clinics, and oncology centers.
  • Distribution Channels: Covers hospital, online, and retail pharmacies.
  • Packaging Formats: Encompasses on-body injectors, pre-filled syringes, and vials.
  • Sales Models: Addresses authorized generic, biosimilar, and branded pathways.
  • Regional Coverage: Analyzes Americas (including key US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including major Western European and emerging markets), and Asia-Pacific (including China, Japan, India, Australia, South Korea, and other dynamic markets).
  • Target Companies: Explores developments among Amgen Inc., Sandoz International GmbH, Coherus BioSciences, Pfizer Inc., Biocon Ltd., Viatris Inc., Celltrion Inc., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., and Apotex Inc.

Key Takeaways

  • Long-acting G-CSF therapies are moving toward advanced sustained-release delivery, reducing injection frequency and improving patient experience.
  • Biosimilar competition has intensified, prompting originator firms to differentiate via novel formulations, collaborations, and enhanced patient support programs.
  • Strategic alliances between biotech and contract development organizations are accelerating time-to-market for innovative pipeline products.
  • Digital health tools and patient monitoring platforms are now integral for adherence tracking, supporting a holistic approach in oncology care.
  • Manufacturing efficiencies—such as adoption of continuous bioprocessing and single-use systems—are minimizing contamination risks and supporting scalable supply.
  • Regulatory adaptations are streamlining approvals and encouraging a more agile response to evolving market needs at regional and global levels.

Tariff Impact: Navigating the United States 2025 Environment

The introduction of 2025 US trade tariffs has created downstream pressures on sourcing, cost structures, and distribution logistics for long-acting G-CSF products. Leading manufacturers are re-evaluating procurement, exploring reshoring and nearshore production partners, and adjusting supply networks to ensure continuity. Contract renegotiations and portfolio diversification are shaping new risk management standards. Distributors are leveraging analytics to predict disruptions, while scenario planning and regulatory engagement are critical for addressing pricing and access challenges across the US market.

Methodology & Data Sources

This report utilizes an integrated research framework, combining qualitative interviews with hematology-oncology experts, supply chain professionals, and reimbursement authorities. Primary insights are validated through secondary sources, including published literature, regulatory submissions, proprietary databases, and scenario simulations. All data undergo rigorous quality review to ensure reliability and strategic relevance.

Why This Report Matters

  • Offers targeted recommendations—balancing innovation, cost, and patient engagement—so organizations can effectively navigate regulatory, market, and supply uncertainties.
  • Supports informed resource allocation and risk management by highlighting key segmentation, competitive strategies, and actionable regional insights.
  • Guides strategic planning by illuminating the multi-dimensional impact of biosimilars, digital health, and emerging policy shifts on the long-acting G-CSF landscape.

Conclusion

The long-acting granulocyte-colony stimulating factor market is entering a period of accelerated growth and transformation. Decision-makers equipped with this analysis are well positioned to navigate emerging complexities and harness new opportunities in supportive oncology care.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of biosimilar approvals driving price competition in long-acting G-CSF therapies
5.2. Strategic partnerships between biotech firms and contract manufacturers enhancing supply scalability of long-acting G-CSF
5.3. Emergence of next-generation PEGylated G-CSFs targeting extended dosing intervals in neutropenia management
5.4. Clinical trial data demonstrating improved patient adherence with on-body injector devices for long-acting G-CSF
5.5. Growing interest in subcutaneous delivery innovations to reduce injection site reactions in G-CSF treatments
5.6. Regulatory harmonization efforts accelerating global market access for novel long-acting G-CSF formulations
5.7. Cost-benefit analyses favoring adoption of pegfilgrastim biosimilars in hospital formulary management strategies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Long-acting Granulocyte-Colony Stimulating Factor Market, by Product Type
8.1. Introduction
8.2. Lipegfilgrastim
8.2.1. Originator
8.3. Pegfilgrastim
8.3.1. Biosimilar
8.3.2. Originator
9. Long-acting Granulocyte-Colony Stimulating Factor Market, by Application
9.1. Introduction
9.2. Chemotherapy-Induced Neutropenia
9.2.1. Hematological Malignancies
9.2.2. Solid Tumors
9.3. Prophylaxis In Surgical Patients
10. Long-acting Granulocyte-Colony Stimulating Factor Market, by End User
10.1. Introduction
10.2. Homecare Settings
10.3. Hospitals
10.3.1. Community Hospitals
10.3.2. Tertiary Care Hospitals
10.4. Research Institutes
10.5. Specialty Clinics
10.5.1. Day Care Clinics
10.5.2. Oncology Centers
11. Long-acting Granulocyte-Colony Stimulating Factor Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Long-acting Granulocyte-Colony Stimulating Factor Market, by Packaging Format
12.1. Introduction
12.2. On-Body Injector
12.3. Pre-Filled Syringe
12.4. Vial
13. Long-acting Granulocyte-Colony Stimulating Factor Market, by Sales Model
13.1. Introduction
13.2. Authorized Generic
13.3. Biosimilar
13.4. Branded
14. Americas Long-acting Granulocyte-Colony Stimulating Factor Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Sandoz International GmbH
17.3.3. Coherus BioSciences, Inc.
17.3.4. Pfizer Inc.
17.3.5. Biocon Ltd.
17.3.6. Viatris Inc.
17.3.7. Celltrion, Inc.
17.3.8. Teva Pharmaceutical Industries Ltd.
17.3.9. Samsung Bioepis Co., Ltd.
17.3.10. Apotex Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET: RESEARCHAI
FIGURE 28. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET: RESEARCHSTATISTICS
FIGURE 29. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET: RESEARCHCONTACTS
FIGURE 30. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ORIGINATOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PROPHYLAXIS IN SURGICAL PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PROPHYLAXIS IN SURGICAL PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DAY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DAY CARE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ON-BODY INJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY ON-BODY INJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY AUTHORIZED GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY AUTHORIZED GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 132. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 133. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 134. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 135. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 136. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 137. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 140. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 141. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 144. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 145. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 146. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 147. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 150. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 151. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 152. CANADA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 154. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 156. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 157. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 158. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 159. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 162. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 163. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 168. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 169. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 172. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 173. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 174. MEXICO LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PACKAGING FORMAT, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY SALES MODEL, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY LIPEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY PEGFILGRASTIM, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM LONG-ACTING GRANULOCYTE-COLONY STIMULATING FACTO

Companies Mentioned

The companies profiled in this Long-acting Granulocyte-Colony Stimulating Factor market report include:
  • Amgen Inc.
  • Sandoz International GmbH
  • Coherus BioSciences, Inc.
  • Pfizer Inc.
  • Biocon Ltd.
  • Viatris Inc.
  • Celltrion, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Samsung Bioepis Co., Ltd.
  • Apotex Inc.

Related Reports

PEGylated Granulocyte-Colony Stimulating Factor Market - Global Forecast 2025-2030 - Product Image

PEGylated Granulocyte-Colony Stimulating Factor Market - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
G-CSF (Granulocyte Colony Stimulating Factor) Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

G-CSF (Granulocyte Colony Stimulating Factor) Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Granulocyte-Colony Stimulating Factor Market - Global Forecast 2025-2030 - Product Image

Granulocyte-Colony Stimulating Factor Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
G-Csf (Granulocyte Colony Stimulating Factors) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

G-Csf (Granulocyte Colony Stimulating Factors) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2025 - Product Image

G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.